Licensed clinic & professional formulary
PureVital logo
Formulary / GLP Weight Loss Vials / Retatrutide
Retatrutide — PureVital
PureVital
VialFeaturedIn stock

Strength

36mg /3ml

Total API

108 mg

Form

Vial

Brand

PureVital

GLP Weight Loss Vials

Retatrutide

Investigational-class triple agonist interest for specialist clinics

PV-RETATRUTIDE-36MG3ML

Professional price

$419.99

View monograph

Retatrutide is discussed in metabolic research as a triple agonist (GLP-1, GIP, and glucagon pathways). PureVital lists clinic vial and pen presentations for licensed programs evaluating this option under appropriate professional governance. Presentation: 36mg /3ml (Vial); total API 108 mg. For licensed clinics and practitioners.

  • Investigational-class triple agonist interest for specialist clinics
  • Strength: 36mg /3ml
  • Total API: 108 mg
  • Vial presentation for licensed clinic programs
Licensed clinic formulary
Label-first SKU detail
Wholesale & bulk desk

PureVital Clinical Formulary — Strength & Volume updates April 2026

Mechanism themes

Receptor and pathway context written for clinic teams.

Clinic-use references

Titration and presentation notes — not patient prescriptions.

Safety & regulatory

Precautions, interactions, and status framing in one monograph.

Clinical monograph

Professional product details

Investigational-class triple agonist interest for specialist clinics. Structured for licensed clinics — mechanism, clinic-use themes, safety, and package clarity in one place.

Compound family

retatrutide

Overview

Retatrutide is discussed in metabolic research as a triple agonist (GLP-1, GIP, and glucagon pathways). PureVital lists clinic vial and pen presentations for licensed programs evaluating this option under appropriate professional governance.

Label-first clinic supply presentation

Contents of the package

What arrives for this PureVital SKU

  • 1 × 36mg /3ml vial presentation
  • Active listing: Retatrutide
  • Total API (label): 108 mg
  • SKU PV-RETATRUTIDE-36MG3ML
  • For parenteral clinic use as directed by the licensed prescriber
  • PureVital professional clinical formulary supply

About Retatrutide

Triple-agonist biology is of high interest for refractory obesity pathways. Clinics should treat protocols as specialist-supervised and evidence-evolving.

Mechanism highlights

LigandReceptorcascadeCliniceffect
  • GLP-1 / GIP incretin signaling for appetite and metabolic control
  • Glucagon-pathway engagement studied for energy expenditure effects
  • Requires careful clinical selection and monitoring frameworks

Clinic use notes

01

Start low

02

Assess GI

03

Escalate

04

Maintain

  • Reserve for appropriately screened patients in supervised programs
  • Verify vial/pen concentration before titration planning
  • Track GI tolerance, vitals, and labs per clinic SOP

Safety considerations

  • Expect incretin-class GI effects; escalate cautiously
  • Specialist review for complex comorbidity profiles
  • Counsel patients that research and labeling status continue to evolve

Regulatory context

Availability and approval status differ from established branded dual/single agonists. Confirm current regulatory posture before protocol adoption.

Educational formulary information for licensed clinics and practitioners only. PureVital presents professional supplement / wellness formulary items — not regular medicines. Final presentation choice, titration, and monitoring remain clinical decisions. Not intended to diagnose, treat, cure, or prevent any disease.

Continue browsing

Related formulary items

Same category presentations clinics often review together.

View GLP Weight Loss Vials →